FindTrial
Sign In

A study to understand the use and scope of drug levels monitoring in patients given voriconazole for invasive fungal diseases.

A prospective study on Therapeutic Drug Monitoring guided decision making Of voriconazole therapy for invasive fungal diseases. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/09/094962
Enrollment
15
Registered
2025-09-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B44- Aspergillosis Health Condition 2: B37- Candidiasis Health Condition 3: B470- Eumycetoma Health Condition 4: B38- Coccidioidomycosis Health Condition 5: B45- Cryptococcosis Health Condition 6: B479- Mycetoma, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4: Nil: Nil Intervention5: Nil: Nil

Sponsors

IPGMER and SSKM Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients attending OPD or admitted as inpatients of IPGMER and SSKM Hospital. The patients must be started on voriconazole within the last 3 days of screening by their treating physician and Participants must be willing to give informed consent for study participation.

Exclusion criteria

Exclusion criteria: Patients taking additional systemic antifungal drugs.

Design outcomes

Primary

MeasureTime frame
To estimate the trough concentration of voriconazole in clinically suspected invasive fungal disease patients on day 3 to 5 of drug initiationTimepoint: Voriconazole trough concentrations between day 3 to day 5 and between week 3 to week 5 from drug initiation. Follow up at 8 weeks and 12 weeks from drug initiation—

Secondary

MeasureTime frame
To evaluate the effectiveness and safety along with clinical outcome in patients undergoing therapeutic drug monitoring of voriconazoleTimepoint: 18 months from incepton—

Countries

India

Contacts

Public ContactDr Suparna Chatterjee

IPGMER and SSKM Hospital

drsupchat@gmail.com03322041371

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026